InsiderTrades.com logo

PSTV Insider Trading

Insider Ownership Percentage: 0.79%
Insider Buying (Last 12 Months): $64,100.00
Insider Selling (Last 12 Months): $0.00

Plus Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Plus Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Plus Therapeutics Share Price & Price History

Current Price: $4.80
Price Change: ▲ Price Increase of +0.88 (22.45%)
As of 04/10/2026 05:00 PM ET

This chart shows the closing price history over time for PSTV up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Plus Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/4/2025Andrew John Hugh SimsCFOBuy800$12.75$10,200.002,725View SEC Filing Icon  
8/22/2025Robert P. LenkDirectorBuy4,400$12.25$53,900.005,573View SEC Filing Icon  
9/13/2024Richard J HawkinsDirectorBuy160$37.50$6,000.00607View SEC Filing Icon  
9/11/2024Howard ClowesDirectorBuy200$33.50$6,700.001,059View SEC Filing Icon  
9/10/2024Andrew John Hugh SimsCFOBuy163$31.75$5,175.25392View SEC Filing Icon  
9/10/2024Marc H HedrickCEOBuy320$30.75$9,840.00817View SEC Filing Icon  
5/8/2024Andrew John Hugh SimsCFOBuy196$51.00$9,996.00228View SEC Filing Icon  
5/8/2024Howard ClowesDirectorBuy392$51.00$19,992.00859View SEC Filing Icon  
5/8/2024Marc H HedrickCEOBuy490$51.00$24,990.00497View SEC Filing Icon  
11/20/2023Marc H HedrickCEOSell82$49.00$4,018.006View SEC Filing Icon  
11/15/2023Robert P. LenkDirectorBuy40$44.25$1,770.00966View SEC Filing Icon  
11/13/2023Robert P. LenkDirectorBuy160$35.75$5,720.00926View SEC Filing Icon  
11/10/2023Robert P. LenkDirectorBuy80$36.25$2,900.00766View SEC Filing Icon  
11/8/2023Robert P. LenkDirectorBuy200$41.25$8,250.00518View SEC Filing Icon  
11/6/2023Robert P. LenkDirectorBuy55$37.50$2,062.5078View SEC Filing Icon  
9/13/2023Howard ClowesDirectorBuy279$35.75$9,974.25467View SEC Filing Icon  
9/11/2023Greg PetersenDirectorBuy800$42.50$34,000.00966View SEC Filing Icon  
6/6/2023Howard ClowesDirectorBuy40$99.50$3,980.00188View SEC Filing Icon  
5/3/2023Howard ClowesDirectorBuy100$91.00$9,100.00148View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Plus Therapeutics (NASDAQ:PSTV)

3.28% of Plus Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at PSTV by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Plus Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/23/2026Virtu Financial LLC496,762$0.25M0.0%N/A0.358%Search for SEC Filing on Google Icon
2/18/2026XTX Topco Ltd248,560$0.13M0.0%N/A0.179%Search for SEC Filing on Google Icon
2/13/2026State Street Corp468,893$0.24M0.0%+37.1%0.338%Search for SEC Filing on Google Icon
2/13/2026L1 Global Manager Pty Ltd2,277,703$1.17M0.8%N/A1.640%Search for SEC Filing on Google Icon
2/12/2026Jane Street Group LLC1,023,905$0.53M0.0%N/A0.737%Search for SEC Filing on Google Icon
2/9/2026Geode Capital Management LLC1,402,794$0.72M0.0%+72.5%1.010%Search for SEC Filing on Google Icon
11/17/2025Susquehanna International Group LLP67,264$46K0.0%N/A0.049%Search for SEC Filing on Google Icon
11/17/2025Scientech Research LLC146,654$100K0.0%N/A0.107%Search for SEC Filing on Google Icon
11/4/2025Altium Capital Management LLC918,914$0.63M100.0%N/A0.926%Search for SEC Filing on Google Icon
8/14/2025Jane Street Group LLC117,454$41K0.0%N/A0.194%Search for SEC Filing on Google Icon
5/12/2025Virtu Financial LLC40,030$38K0.0%N/A0.235%Search for SEC Filing on Google Icon
8/7/2024AIGH Capital Management LLC568,681$0.84M0.3%N/A9.977%Search for SEC Filing on Google Icon
11/15/2022Parkman Healthcare Partners LLC1,325,025$0.59M0.2%-13.6%3.943%Search for SEC Filing on Google Icon
8/8/2022Otter Creek Advisors LLC330,168$0.18M0.1%+293.5%1.465%Search for SEC Filing on Google Icon
5/13/2022Parkman Healthcare Partners LLC1,526,316$1.53M0.4%N/A6.875%Search for SEC Filing on Google Icon
5/9/2022Otter Creek Advisors LLC83,901$84K0.0%N/A0.378%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Plus Therapeutics logo
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Read More on Plus Therapeutics

Today's Range

Now: $4.80
Low: $4.10
High: $5.35

50 Day Range

MA: $6.17
Low: $2.92
High: $8.11

52 Week Range

Now: $4.80
Low: $2.90
High: $30.50

Volume

1,307,921 shs

Average Volume

458,859 shs

Market Capitalization

$32.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.03

Who are the company insiders with the largest holdings of Plus Therapeutics?

Plus Therapeutics' top insider investors include:
  1. Robert P Lenk (Director)
  2. Andrew John Hugh Macintyr Sims (CFO)
  3. Howard Clowes (Director)
  4. Greg Petersen (Director)
  5. Marc H Hedrick (CEO)
  6. Richard J Hawkins (Director)
  7. Marc H Hedrick (CEO)
  8. Azeez Hayne (CAO)
Learn More about top insider investors at Plus Therapeutics.

Plus Therapeutics Active Insiders

Marc H. Hedrick
Marc H. Hedrick (Age 63)
CEO
Andrew John Hugh Macintyr Sims
Andrew John Hugh Macintyr Sims (Age 78)
CFO
1 recent trades
Robert P Lenk
Director
Greg Petersen
Director